Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

De-escalation of corticosteroids and clonal remission in UBA1 mutation-driven VEXAS syndrome with 5-azacytidine.

Haematologica - 1 Oct 2024

Trikha Roochi, Kong Kar Lok, Galloway James, Basu Tanya N, Quek Lynn, Wilson Jamie, Gamble Louise, Wong Henna, Best Steven, Kulasekararaj Austin

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Cortex Hormones
Share to Azacitidine
Share to Mutation
Share to Otitis Media and Relapsing Polychondritis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Remission Induction

Share to Treatment Outcome

Share to Ubiquitin-Activating Enzymes

Source

Open in PubMed Open full text

Identifiers

PMID: 38867587
DOI: 10.3324/haematol.2024.285519
PMCID: PMC11446246

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

De-escalation of corticosteroids and clonal remission in UBA1 mutation-driven VEXAS syndrome with 5-azacytidine.PMID 38867587Read ↗

Trisomy 8 clonal expansion during disease progression and azacitidine resistance in VEXAS syndrome: a case report.Semantic proximity Read ↗

VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.Semantic proximity Read ↗

VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management.Semantic proximity Read ↗

Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.Semantic proximity Read ↗

Clinical, laboratory and genetic characteristics of VEXAS syndrome: a study on behalf of GESMD.Semantic proximity Read ↗

Decoding VEXAS syndrome: emerging insights into pathogenesis and clinical management.Semantic proximity Read ↗

VEXAS: A review of current understandings and emerging treatment strategies.Semantic proximity Read ↗

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.Semantic proximity Read ↗

Toward a pathophysiology inspired treatment of VEXAS syndrome.Semantic proximity Read ↗

UBA1 dysfunction in VEXAS and cancer.Semantic proximity Read ↗

Long‐term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndromeSemantic proximity Read ↗

VEXAS Syndrome: Complete molecular remission after hypomethylating therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.